• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
BAO Xingjia, CHEN Xin, WANG Shiru, LING Yunni, ZHANG Jianjun, GAO Yuan. Coamorphous combinations of poorly water-soluble drugs dabigatran etexilate mesylate and tadalafil for improving dissolution and physical stability[J]. Journal of China Pharmaceutical University, 2019, 50(5): 549-559. DOI: 10.11665/j.issn.1000-5048.20190507
Citation: BAO Xingjia, CHEN Xin, WANG Shiru, LING Yunni, ZHANG Jianjun, GAO Yuan. Coamorphous combinations of poorly water-soluble drugs dabigatran etexilate mesylate and tadalafil for improving dissolution and physical stability[J]. Journal of China Pharmaceutical University, 2019, 50(5): 549-559. DOI: 10.11665/j.issn.1000-5048.20190507
shu

Coamorphous combinations of poorly water-soluble drugs dabigatran etexilate mesylate and tadalafil for improving dissolution and physical stability

More Information
    Graphical Abstract
    • Abstract
  • 〓 Dabigatran etexilate mesylate(DE)and tadalafil(TD)are BCS class II drugs with poor water solubility. 〓 In this study coamorphization technique was used to improve their solubilities/dissolutions and hence to enhance their oral absorptions. The coamorphous DE-TD were prepared by solvent-evaporation method and characterized by PXRD, DSC, FTIR and TGA. In addition, dissolution behavior and physical stability were also investigated. Only halo pattern and a single Tg of 119 °C was observed on the PXRD and DSC of the co-evaporated product, respectively, indicating the formation of coamorphous DE-TD. FTIR result suggested that a hydrogen bond was probably formed between N-H group of DE and C==O group of TD. In comparison to crystalline counterparts, coamorphous DE-TD showed a significantly improved intrinsic dissolution rate and prolonged supersaturation time in intrinsic dissolution and supersaturation dissolution studies, respectively. No crystallization was observed under affecting factors testing(30 days)as well as long-term and accelerated stability testing(90 days)for the prepared coamorphous DE-TD under 25°C/60%RH or 40°C/75%RH, while amorphous DE crystalized at 10 days under 25 ℃/75% RH.
    • FullText(HTML)
    • References (33)
  • [1]
    Guo HH,Miao NN,Li TF,et al.Pharmaceutical coamorphous:a newly defined single-phase amorphous binary system[J].Prog Chem(化学进展),2014,26(2/3):478-486.
    [2]
    Qian S,Heng WL,Wei YF,et al.Coamorphous lurasidone hydrochloride-saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior[J].Cryst Growth Des,2015,15(6):2920-2928.
    [3]
    Gao Y,Liao J,Qi X,et al.Coamorphous repaglinide-saccharin with enhanced dissolution[J].Int J Pharm,2013,450(1/2):290-295.
    [4]
    Loebmann K,Strachan C,Grohganz H,et al.Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions[J].Eur J Pharm Biopharm,2012,81(1):159-169.
    [5]
    Qian S, Li Z, Heng WL, et al. Charge-assisted intermolecular hydrogen bond formed in coamorphous system is important to relieve the pH-dependent solubility behavior of lurasidone hydrochloride[J].RSC Adv, 2016,6(108):106396-106412.
    [6]
    Chavan RB,Thipparaboina R,Kumar D,et al.Coamorphous systems:a product development perspective[J].Int J Pharm,2016,515(1/2):403-415.
    [7]
    Chen J,Guo HH,Zhang JJ,et al.Physicochemical characteristics of coamorphous simvastatin-gliclazide[J].J China Pharm Univ(中国药科大学学报),2015,46(3):301-308.
    [8]
    Hernandez I,Baik SH,Pinera A,et al.Risk of bleeding with dabigatran in atrial fibrillation[J].JAMA Intern Med,2015,175(1):18-25.
    [9]
    Schulman S,Kearon C,Kakkar AK,et al.Extended use of dabigatran,warfarin,or placebo in venous thromboembolism[J].N Engl J Med,2013,368(8):709-718.
    [10]
    Daugan A,Grondin P,Ruault C,et al.The discovery of tadalafil:a novel and highly selective PDE5 inhibitor.2:2,3,6,7,12,12a-hexahydropyrazino [1′,2′:1,6] pyrido [3,4-b] indole-1,4-dione analogues[J].J Med Chem,2003,46(21):4533-4542.
    [11]
    Humbert M,Lau EM,Montani D,et al.Advances in therapeutic interventions for patients with pulmonary arterial hypertension[J].Circulation,2014,130(24):2189-2208.
    [12]
    Bendayan D,Shitrit D,Kramer MR.Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension:a pilot study[J].Respirology,2008,13(6):916-918.
    [13]
    Kruger S,Haage P,Breuer C,et al.Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography[J].Chest,2001,120(5):1556-1561.
    [14]
    Chai FJ,Sun LL,Ding YF,et al.A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability[J].Nanomedicine,2016,11(14):1801-1816.
    [15]
    U.S.Food and Drug Administration.Center for drug evaluation and research application number 22-5.12[EB].(2010-12-15)[2019-02-10] .http:// www.accessdata.fda.gov/ drugsatfda_ docs/ nda/ 2010/ 022512Orig1s000TOC.cfm.
    [16]
    Wlodarski K,Sawicki W,Haber K,et al.Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil[J].Eur J Pharm Biopharm,2015,94:106-115.
    [17]
    Wei YF,Ling YN,Su ML,et al.Characterization and stability of amorphous tadalafil and four crystalline polymorphs[J].Chem Pharm Bull,2018,66(12):1114-1121.
    [18]
    Hildebrand JH,Scott RL.The solubility of non electrolytes[M].3rd ed.New York:Reinhold Publishing Corporation,1950:153-173.
    [19]
    Greenhalgh DJ,Williams AC,Timmins P,et al.Solubility parameters as predictors of miscibility in solid dispersions[J].J Pharm Sci,1999,88(11):1182-1190.
    [20]
    Fedors RF. A method for estimating both the solubility parameters and molar volumes of liquids[J].Polym Eng Sci,1974,14(2):147-154.
    [21]
    Mohammad MA, Alhalaweh A, Velaga SP. Hansen solubility parameter as a tool to predict cocrystal formation[J].Int J Pharm,2011,407(1/2):63-71.
    [22]
    Barton AFM.CRC handbook of solubility parameters and other cohesion parameters [M].2nd ed.Florida:CRC Press,1991:160-185.
    [23]
    Wood J,Syarto J,Letterman H.Improved holder for intrinsic dissolution rate studies[J].J Pharm Sci,1965,54(7):1068.
    [24]
    Wang FY,Zhang Q,Zhang ZY,et al.Solid-state characterization and solubility enhancement of apremilast drug-drug cocrystals[J].CrystEngComm,2018,20(39):5945-5948.
    [25]
    Lobmann K,Grohganz H,Laitinen R,et al.Amino acids as co-amorphous stabilizers for poorly water soluble drugs-part 1:preparation,stability and dissolution enhancement[J].Eur J Pharm Biopharm,2013,85(3):873-881.
    [26]
    Ceric H,Dogan J,Leksic E,et al.Solid state forms of dabigatran etexilate,dabigatran etexilate mysylate and processes for preparation thereof: WO,2012027543A1[P].2012-03-01 [2019-02-16] .
    [27]
    Wizel S,Vant A,Diller D,et al.Tadalafil crystal forms and processes for preparing them:WO,2006050458A2[P].2006-11-11 [2019-02-16] .
    [28]
    Yu L.Amorphous pharmaceutical solids:preparation,characterization and stabilization[J].Adv Drug Deliv Rev,2001,48(1):27-42.
    [29]
    Wlodarski K,Sawicki W,Paluch KJ,et al.The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil[J].Eur J Pharm Sci,2014,62:132-140.
    [30]
    Vyas V,Sancheti P,Karekar P,et al.Physicochemical characterization of solid dispersion systems of tadalafil with poloxamer 407[J].Acta Pharm,2009,59(4):453-461.
    [31]
    Qian S,Wang SS,Li Z,et al.Charge-assisted bond N+-H mediates the gelation of amorphous lurasidone hydrochloride during dissolution[J].Int J Pharm,2017,518(1/2):335-341.
    [32]
    Guzman HR,Tawa M,Zhang Z,et al.Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations[J].J Pharm Sci,2007,96(10):2686-2702.
    [33]
    Raina SA,Zhang GGZ,Alonzo DE,et al.Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs[J].J Pharm Sci,2014,103(9):2736-2748.
    • Related Articles

  • Related Articles

    [1]WANG Jiang, ZHAO Xueyan, FANG Weirong. Research progress in STAT3/Th17 cells and Sjögren syndrome[J]. Journal of China Pharmaceutical University, 2024, 55(3): 420-428. DOI: 10.11665/j.issn.1000-5048.2023041805
    [2]SHI Xiaoni, YANG Shaoqi, CHENG Yusi, CHAO Jie. PPP2R3A promotes silicosis by regulating the expression of p53[J]. Journal of China Pharmaceutical University, 2022, 53(4): 490-497. DOI: 10.11665/j.issn.1000-5048.20220412
    [3]LIU Li, ZHANG Qianwen, NONG Cheng, ZHANG Xi, XU Xiaoting, Mohammed Ismail, XIAO Li, JIANG Zhenzhou, ZHANG Luyong, SUN Lixin. Research progress of lncRNA regulating signal transduction pathway in liver diseases[J]. Journal of China Pharmaceutical University, 2020, 51(3): 277-286. DOI: 10.11665/j.issn.1000-5048.20200304
    [4]WAN Nanyan, JIANG Cuihua, GAO Meng, ZHANG Jian, YIN Zhiqi, PAN Ke. Paeoniflorin inhibits programmed cell death-1-ligand 1 expression in HepG2 cells by regulating JAK/STAT3 signal pathway[J]. Journal of China Pharmaceutical University, 2019, 50(2): 213-221. DOI: 10.11665/j.issn.1000-5048.20190213
    [5]QIAO Jianan, WANG Tingfang, ZHANG Can. Design, synthesis and bioactivities of 4-(3-sulfonylbenzene)amino-6-formylpyrrole［2, 3-d］ pyrimidine derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(5): 554-562. DOI: 10.11665/j.issn.1000-5048.20170508
    [6]TAN Chengning, HUANG Jinghan, LI Chunhong, XIA Zhining, YANG Fengqing. Applications of proteomics in the study of cell signal pathways[J]. Journal of China Pharmaceutical University, 2017, 48(4): 384-395. DOI: 10.11665/j.issn.1000-5048.20170402
    [7]LIU Xiaofei, WANG Tingfang, JU Caoyun, ZHANG Can. Synthesis and JAK2 inhibitory activities of 4-phenyl-pyrrolo［2, 3-d］pyrimidine derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(2): 150-156. DOI: 10.11665/j.issn.1000-5048.20170204
    [8]WANG Jing-song, SHEN Jing, ZHANG Ting, TANG Cong, REN Tian-nian, XI Tao. Ursolic acid downregulates COX-2 expression by suppressing the activation of ERK in A549 cells[J]. Journal of China Pharmaceutical University, 2011, 42(1): 68-72.
    [9]Changes of Expression and Functions of Dipeptide Transporter after Anoxia/reoxygenation in Caco-2 Cells[J]. Journal of China Pharmaceutical University, 2003, (1): 76-79.
    [10]Effects of 3 Tyrphostins on Recombinant Human Protein Kinase CK2 Holoenzyme[J]. Journal of China Pharmaceutical University, 2001, (6): 51-56.

  • Cited by

    Periodical cited type(6)

    1. 朱秋梦，石佳琦，吕玮，张昕，肖云峰. 丁香酚对大鼠心肌缺血再灌注损伤的抑制作用及其机制. 山东医药. 2024(05): 7-11 .
    2. 张艺馨，李双. 依托咪酯调控circ-CCND1/miR-214-5p分子轴减轻缺氧/复氧诱导的心肌细胞损伤. 中国药师. 2022(01): 6-11 .
    3. 徐季轩，马晓静，陈泓颖，高小力，佟海英，屠鹏飞，安超，柴兴云. 我国主要少数民族医药防治缺血性心脏病研究概述. 中国实验方剂学杂志. 2022(17): 235-247 .
    4. 赵汴霞，宛蕾. 人参皂苷Rd对人脐静脉内皮细胞凋亡保护的作用研究. 河南医学高等专科学校学报. 2022(04): 399-405 .
    5. 劳慧敏，李燕宁，韩成恩，陈梦琦. 养心活血解毒方对CVB3诱导的病毒性心肌炎小鼠心肌损伤的保护作用. 时珍国医国药. 2021(03): 544-547 .
    6. 张文超，方秧青，钟静红，张明. 粉防己碱通过JAK2-STAT3途径减轻心肌缺血/再灌注损伤. 解剖学杂志. 2021(04): 291-294+318 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (709) PDF downloads (1363) Cited by(8)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：292781

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return